BC Platforms has secured a multi-year contract to work with three Finnish Hospital District owned Biobanks (Clinical Biobanks) on improving access to, and automated management of, phenotypic, genomic, and clinical
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Nordic Biomarker is partnering with private equity company Procuritas. ”Together with our new Swedish majority owner Procuritas, who share our vision for the company to become a leading global supplier
BioArctic has announced that the US Patent and Trademark Office (USPTO) has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of
Kaiku Health and Roche are entering a strategic partnership in digital patient monitoring and management (DPMM). Kaiku Health and Roche aim to deploy digital tools to provide real-time symptom management
BICO has acquired all the shares in San Diego-based Allegro 3D for an up-front enterprise value of USD 6 million. Additionally, the shareholders can receive USD 5 million in an
The two companies have announced a collaboration to create a portfolio of novel research programmes to develop transformational medicines. The collaborators will explore opportunities to apply Flagship’s bioplatforms, an ecosystem
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based
The global professional services firm ZS has acquired Danish bioinformatics and systems biology company, Intomics. Founded in Copenhagen, Denmark in 2008, Intomics accelerates and optimizes pharmaceutical drug discovery and development
Aqilion has nominated Girtab, a program from the company’s research activities, for further preclinical and clinical development. The goal of Girtab is to develop a new treatment for chronic inflammatory
AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi, in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic
The two collaborators have signed an agreement with the aim to advance genomics and precision medicine and its implementation in healthcare. The joint partnership will focus on the development and
Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor
Ilya Pharma has announced that FDA have cleared an IND for its lead candidate ILP100-Topical and that the company is immediately accelerating preparations for large adaptive Phase 2 study, designed
Ultomiris has been approved for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease.
Sponsored content
Commissioning, Qualification & Validation: Fundamental for pharmaceutical products & life-saving therapies
GxP facilities must comply with regulatory requirements. Doing so ensures that products are manufactured and delivered safely under meticulous regulation and standards. Genesis AEC uses Vaisala data loggers with vlog software to save time on mapping applications.
The COVID-19 pandemic
Sweden’s Minister of Health and Social Affairs, Lena Hallengren, has officially inaugurated Valneva Sweden’s new COVID-19 vaccine manufacturing facility, the first and only one of its kind in Sweden. “The
New research from Karolinska Institutet shows that a booster shot of mRNA vaccine to individuals who have received two doses of inactivated vaccine offers the same level of protection against
Several months after COVID-19, one is still at an increased risk of blood clot and bleeding, shows research from Umeå University. The researchers analyzed all COVID-19 cases in Sweden from the
Residential exposure to ambient air pollutants is linked to an elevated risk of SARS-CoV-2 infection, an observational study of young adults in Stockholm, Sweden shows. The study was conducted by
Professor Trine Hyrup Mogensen from Aarhus University will study why some people suffer from serious COVID-19 infections, while others do not become ill at all, even when exposed to massive
Sponsored content
Shimadzu Denmark Office has its own management
The Danish office of Shimadzu was opened in September 2020 in Ballerup on the outskirts of Copenhagen and features the entire range of analytical instrumentation solutions. Joachim Holm is the first local managing director of Shimadzu Denmark. The 43-year-old family man studied pharmacy and business and possesses many years of experience in sales management and business development. In his new role as managing director, Holm wishes to integrate Shimadzu Denmark even further into the Scandinavian market.
Drug and device development
The Regional Health Authorities in Norway has recently decided to reimburse patients who are included in the first expansion cohort in IMPRESS-Norway according to a pay-for-performance model. IMPRESS-Norway is a
Immunicum has announced updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead development program DCP-001, a novel therapeutic option for acute myeloid leukemia (AML) maintenance
Targovax has entered into a clinical trial collaboration agreement with Oslo University Hospital (OUS) to run a phase 1/2 study testing polyvalent mutant RAS vaccine TG01 in multiple myeloma (MM)
Nykode Therapeutics has announced positive interim results from its Phase 2 VB C-02 trial of VB10.16, its wholly-owned therapeutic cancer vaccine, in combination with the PD-L1 inhibitor atezolizumab in patients
Cyxone has announced results from its ongoing collaboration with Medical University of Vienna. Cyxone and its research partner, the Medical University of Vienna, announced pre-clinical data further supporting T20K as
Profile
Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real
In a new job
In her new role as Chief Executive Officer at Medicon Valley Alliance, Anette Steenberg aims to zoom in on the strongholds of the region as well as strengthening the framework
Orion Corporation’s Board of Directors has appointed Liisa Hurme as President and CEO of Orion Corporation and the Chair of the Executive Management Board of the Orion Group as of
EXACT Therapeutics has announced that its Board of Directors has appointed Per Walday as Chief Executive Officer. Per Walday has experience from research to commercialization of therapeutics and medical devices
Careers
How do you take an invention further and make the right decisions to protect your innovation? Patent engineer Maria Lundström provides a helping hand in the delicate processes of patents,
Read the latest issue of our magazine!
No 02 2022 // This issue includes in-depth articles about successful company growth within life sciences. What lessons can we learn from the journeys, progress, setbacks and challenges of other Nordic companies? What perspectives and advice can the region’s investors and business advisors provide?
In addition, Jutta Heix, Head of International Affairs at Oslo Cancer Cluster, describes how she is accelerating the development of new cancer treatments and diagnostics – connecting and helping innovators and putting Norwegian oncology on the global map, and Bengt Mattson, special adviser at Lif, writes about health in the shadow of war. We take a closer look at four different career choices within drug discovery; their daily tasks, what challenges they encounter and what drives them in their different roles.
This, and much more, in our latest issue – out now!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
This European event will be held in-person on 16-18 May, in Milan, and digital partnering will also be possible on 23-24 May. This is one of Europe’s premier international showcase
BIO is thrilled to be back in person for the 2022 International Convention happening in San Diego, CA June 13-16. The Convention theme ‘LIMITLESS’ is our commitment to unlocking possibilities for our members
Since its inception in 2013, NLSDays has nurtured a community of people from the world of life science, and created a unique place to do business. This annual event offers an informal
The latest research news from the Nordic region
Science Article
Scientists at deCODE genetics have together with their Nordic collaborators published the largest genome-wide association study to date on rheumatoid arthritis (RA), including over thirty thousand cases and one million
The Nobel Laureates in Medicine 2021 revealed the mechanisms that underpin the different sensations of temperature and touch. Their discoveries have led to a better understanding of how the nervous
Elicera Therapeutics have announced the publication of a scientific article describing the mechanism-of-action of the company’s universal CAR T-cell enhancement technology platform iTANK in Nature Biomedical Engineering. Proof-of-concept data presented
This weekend most countries in Europe will spring forward one hour. We take a closer look upon how our inner clock regulates critical functions like behavior, hormone levels, sleep, body
The largest genetic study of migraine to date reveals new genetic risk factors. In the largest genome study of migraine yet, researchers have more than tripled the number of known
One of Nobel Laureate David Julius’ greatest joys is when people in his lab show him exciting data and make their own discoveries, and as a scientist and educator his
Nordic Life Science
The latest clinical trials
Immunicum has announced updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead development program DCP-001, a novel therapeutic option for acute myeloid leukemia (AML) maintenance
Targovax has entered into a clinical trial collaboration agreement with Oslo University Hospital (OUS) to run a phase 1/2 study testing polyvalent mutant RAS vaccine TG01 in multiple myeloma (MM)
Nykode Therapeutics has announced positive interim results from its Phase 2 VB C-02 trial of VB10.16, its wholly-owned therapeutic cancer vaccine, in combination with the PD-L1 inhibitor atezolizumab in patients
Cyxone has announced results from its ongoing collaboration with Medical University of Vienna. Cyxone and its research partner, the Medical University of Vienna, announced pre-clinical data further supporting T20K as
Affibody, Acelyrin and Inmagene Biopharmaceuticals have announced that a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) met its primary endpoint of ACR50.
Immunicum has announced the publication of a scientific abstract that discloses new preclinical data on DCP-001, the company’s lead clinical candidate, in combination with 5’-azacitidine (5-AZA), a hypomethylating agent, and
AI Medical Technologies announces the start of a clinical trial at 30 Swedish primary care facilities with Dermalyser, a diagnostic decision support system empowered with advanced artificial intelligence (AI). The
Paolo Macchiarini who made headlines for pioneering surgery is charged with aggravated assault over procedure. Macchiarini has gone on trial in Sweden charged with aggravated assault, 11 years after he
Bavarian Nordic has announced the dosing of the first subject in the Phase 3 VANIR clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV in older
Sign up to our newsletter